CareDx agreed to acquire Naveris for up to $260 million, expanding its precision oncology diagnostics footprint. The transaction gives CareDx access to NavDx, a liquid biopsy test for HPV-driven cancers that measures tumor-naïve minimal residual disease via fragments of viral DNA. The deal includes an upfront cash payment of $160 million plus up to $100 million in revenue milestones. Naveris operates high-complexity labs in Massachusetts and North Carolina and reported $34 million in unaudited revenue in 2025. CareDx framed the acquisition as targeted to HPV-mediated solid tumors where longitudinal molecular monitoring is reimbursed.